## Review setup
- **Input scope** Full manuscript text (abstract, introduction, methods, results, discussion, conclusion) as provided by the user.
- **Assessment boundary** Scientific content, methodological rigor, validity of claims, and alignment with Nature-style criteria. Editorial and formatting issues are considered only where they affect scientific clarity.
- **Shared manuscript claim summary** The authors propose a consensus binding hypothesis for Smad3-FoxH1 inhibitors using molecular docking and 250 ns molecular dynamics simulations on 33 dimeric compounds from PubChem, identifying Asn320 as a key interaction residue and a potential novel hydrophobic site around Tyr323.
- **Visible evidence base** Abstract, full methods, results, discussion, conclusion, and references to supporting figures/tables (S1–S8, Figs 1–6, Tables 2–4). Specific numerical data for RMSD/RMSF values, hydrogen bond occupancies, and ADMET predictions are partially reported in text but not fully quantified.
- **Missing materials affecting confidence** Full figures and tables (S1–S8, Figs 1–6, Tables 2–4) are not provided; exact simulation parameters (e.g., temperature coupling, pressure coupling, equilibration details) are partially described; no raw data or trajectory files; no validation of docking poses against experimental structures; no statistical analysis of hydrogen bond persistence; no comparison with known Smad3 inhibitors beyond SIS3.

## Reviewer
- **Overall assessment** The manuscript addresses a relevant gap in Smad3 inhibitor development by attempting to establish a binding hypothesis through computational methods. The study is well-motivated and the workflow (homology modeling, docking, MD simulation, hydrogen bond analysis) is standard. However, several technical and interpretive issues undermine the strength of the conclusions. The claim that Asn320 is an "efficient inhibition site" is based on only two compounds and lacks experimental or statistical validation. The identification of a novel Tyr323 site is intriguing but insufficiently characterized. The ADMET analysis is descriptive and not integrated into the binding hypothesis. Overall, the study provides preliminary computational insights but does not yet establish a robust, generalizable binding hypothesis.
- **Who would be interested in the results, and why** Computational chemists and medicinal chemists working on TGFβ/Smad3 pathway modulation, particularly those interested in cardiovascular fibrosis. The study offers a potential starting point for lead optimization and highlights residues that could be targeted in future drug design. Researchers using MD simulations for binding site characterization may also find the methodological workflow relevant.
- **Major strengths** (1) The study addresses a clinically relevant target (Smad3 in ASCVD) with a clear rationale. (2) The use of a large, publicly available dataset (PubChem 630) with a consistent biological assay is a strength. (3) The combination of docking and MD simulation is appropriate for generating binding hypotheses. (4) The identification of a potential novel binding site (Tyr323) is an interesting finding that could open new avenues. (5) The ADMET screening provides a practical filter for candidate selection.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Validity of core claim
  - **Claim pointer** "Asn320 in Smad3 provides an efficient inhibition site for the two most potent small inhibitors (SM1 and SM2) of Smad3-FoxH1 binding."
  - **Evidence pointer** Results, "MD simulation of the docked complexes", Table 2, Fig 3
  - **Concern** The claim that Asn320 is an "efficient inhibition site" is based on only two compounds (SM1 and SM2) that share high structural similarity. This is insufficient to establish a generalizable binding hypothesis. No mutagenesis, free energy calculations, or experimental validation are provided to support the functional importance of Asn320. The hydrogen bond persistence is described qualitatively, and no quantitative occupancy data are reported.
  - **Why it matters** The central conclusion of the paper rests on this claim. Without broader evidence across diverse scaffolds or experimental confirmation, the hypothesis remains speculative and cannot guide lead optimization reliably.
  - **Resolution test** Provide quantitative hydrogen bond occupancy data for Asn320 across all 13 stable complexes. Include additional diverse compounds that form stable interactions with Asn320. Alternatively, perform free energy perturbation or MM-PBSA calculations to estimate binding affinities. Ideally, validate with site-directed mutagenesis or a published Smad3 mutant study.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness of MD simulations
  - **Claim pointer** "The results of MD simulations suggest that only 13 out of 33 docked ligands form stable interactions within the binding site of FoxH1 protein."
  - **Evidence pointer** Methods, "Molecular dynamic simulations"; Results, "MD simulation of the docked complexes"
  - **Concern** The criteria for "stable interactions" are not defined. No threshold for RMSD stability, hydrogen bond persistence, or ligand residence time is provided. The simulation length (250 ns) may be insufficient for ligands with slow binding kinetics. Additionally, the force field parameters for ligands are not described (e.g., GAFF, CGenFF), and the method for generating ligand topologies is not stated. The equilibration protocol is only partially described (NVT and NPT for 100 ps each), which may be insufficient for system equilibration.
  - **Why it matters** Without clear stability criteria and adequate simulation setup, the classification of 13 stable versus 20 unstable complexes is subjective and not reproducible. This undermines the reliability of all subsequent interaction analyses.
  - **Resolution test** Define quantitative criteria for stability (e.g., RMSD < 0.3 nm for the last 100 ns, hydrogen bond occupancy > 50%). Report ligand force field parameters and topology generation method. Extend equilibration or justify the current protocol. Provide representative RMSD and RMSF plots for all 33 complexes, not just selected examples.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Novelty and significance of the Tyr323 site
  - **Claim pointer** "Two compounds (SM8 and SM19) detached from the FoxH1 binding site and formed a highly stable complex around Tyr323 via hydrophobic complementarity, suggesting a new binding site for modulation of Smad3 activity."
  - **Evidence pointer** Results, "Novel binding site for SM8 and SM19 from group-III", Figs 5 and 6
  - **Concern** The identification of a novel binding site is potentially interesting, but the evidence is limited to two compounds. The functional relevance of this site is unclear, as Tyr323 is not reported to be involved in FoxH1 binding. The authors do not discuss whether this site is druggable or whether it could allosterically modulate Smad3 function. The claim that this is a "new binding site for modulation" is speculative without functional data.
  - **Why it matters** Overclaiming a novel site without functional validation could mislead future drug design efforts. The site may be an artifact of the truncated protein model (C-terminal residues removed) or a non-specific hydrophobic interaction.
  - **Resolution test** Perform additional simulations with full-length Smad3 or a construct that includes the C-terminal region. Test whether SM8 and SM19 inhibit Smad3-FoxH1 binding in vitro. Use cavity detection and druggability prediction tools (e.g., DoGSiteScorer) to assess the potential of the Tyr323 site. Discuss the allosteric implications with reference to known Smad3 regulatory mechanisms.
  - **Concern ID** R1-M4
  - **Severity** Major
  - **Blocking** No
  - **Axis** Integration of ADMET data
  - **Claim pointer** "ADMET properties can provide valuable insights into the physiochemical properties of a compounds that are important for a potential drug candidate."
  - **Evidence pointer** Results, "ADMET analysis of compounds", S5 Table
  - **Concern** The ADMET analysis is presented as a separate descriptive section without integration into the binding hypothesis. The authors identify SM8, SM11, SM25, and SM31 as "best possible candidates" but do not explain how ADMET properties relate to binding affinity or selectivity. The selection criteria for "best" are not defined. Additionally, the ADMET predictions are not validated against experimental data.
  - **Why it matters** The ADMET section appears as an add-on rather than a meaningful part of the study. Without clear integration, it does not strengthen the binding hypothesis or provide actionable guidance for lead optimization.
  - **Resolution test** Define explicit criteria for candidate selection (e.g., logS > -5, no AMES toxicity, no hERG inhibition). Discuss how ADMET properties correlate with the binding hypothesis. If possible, compare predictions with known experimental data for similar compounds.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity of methods
  - **Affected element** Homology modeling
  - **Evidence pointer** Methods, "Protein model preparation and molecular dynamic simulation"
  - **Issue** The description of homology modeling is incomplete. The template selection criteria, sequence identity, and alignment quality are not reported. The statement "1mjs structure was of higher resolution (1.91Å) but contained missing regions" is inconsistent with the earlier mention of "1mjs" and "1mk2" (typo: "1mks" in Results).
  - **Required correction** Clarify template selection, report sequence identity and alignment coverage. Correct the typo in the Results section ("1mks" should be "1mk2").
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Data presentation
  - **Affected element** Hydrogen bond analysis
  - **Evidence pointer** Results, Tables 2–4
  - **Issue** Hydrogen bond interactions are described in text but not systematically tabulated with occupancy percentages or distances. The reader cannot assess the strength or persistence of these interactions.
  - **Required correction** Provide a comprehensive table listing hydrogen bond donors, acceptors, occupancy, and average distances for all stable complexes.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Statistical rigor
  - **Affected element** Classification of stable vs. unstable complexes
  - **Evidence pointer** Results, "MD simulation of the docked complexes"
  - **Issue** The classification of 13 stable complexes is presented without statistical justification. No error bars or replicate simulations are reported.
  - **Required correction** State whether simulations were performed in duplicate or triplicate. If not, acknowledge this limitation and discuss its impact on the conclusions.
  - **Concern ID** R1-m4
  - **Severity** Minor
  - **Axis** Literature context
  - **Affected element** Discussion
  - **Evidence pointer** Discussion section
  - **Issue** The discussion does not compare the proposed binding hypothesis with existing structural or computational studies of Smad3 inhibitors. The authors mention SIS3 but do not discuss its binding mode or how their findings relate to it.
  - **Required correction** Add a paragraph comparing the proposed binding sites with known Smad3 inhibitor binding modes and discuss how the findings extend or contradict previous work.
- **Technical failings that need to be addressed before the case is established** (1) Lack of quantitative stability criteria for MD simulations (R1-M2). (2) Insufficient evidence for the Asn320 claim, based on only two similar compounds (R1-M1). (3) Incomplete description of ligand parameterization and simulation setup. (4) No validation of the homology model beyond basic metrics (DOPE, Ramachandran). (5) The Tyr323 site is not functionally contextualized (R1-M3).
- **Assessment against Nature-style criteria**  
  *Originality*: Moderate. The application of MD simulations to a large dataset for Smad3 binding hypothesis generation is not entirely novel, but the focus on dimeric inhibitors and the identification of a potential new site adds some originality.  
  *Scientific importance*: Moderate. Smad3 is a relevant therapeutic target, but the study is purely computational and does not provide experimental validation. The importance would be higher if the binding hypothesis were confirmed experimentally.  
  *Interdisciplinary readership*: Limited. The manuscript is primarily of interest to computational and medicinal chemists. It lacks the broader biological or clinical context that would attract a wider readership.  
  *Technical soundness*: Weak to moderate. The workflow is standard, but the lack of quantitative criteria, incomplete methods, and absence of validation reduce technical rigor.  
  *Readability for nonspecialists*: Moderate. The manuscript is generally clear but includes technical jargon and equations that may be challenging for nonspecialists. The abstract is accessible, but the methods and results require domain expertise.
- **Recommendation posture** Currently not established from the provided evidence. The study presents a reasonable computational workflow and some interesting observations, but the core claims are insufficiently supported. The manuscript would require substantial revisions, including quantitative stability criteria, broader compound analysis, and ideally experimental validation, before the binding hypothesis can be considered established. A resubmission after major revisions could be considered.

## Risk / unsupported claims
- The claim that Asn320 is an "efficient inhibition site" is unsupported beyond two structurally similar compounds.
- The identification of a "new binding site" around Tyr323 is speculative without functional or druggability analysis.
- The statement that "13 out of 33 docked ligands form stable interactions" is not backed by defined criteria or quantitative data.
- The ADMET-based selection of "best possible candidates" lacks explicit criteria and integration with the binding hypothesis.
- The claim that the binding hypothesis "can act as a scaffold for lead optimization" is premature without experimental validation.